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The spread of glycopeptide-resistant enterococcal 
infections across the continental USA has been well 
documented in the current decade [1,2]. This 
expansion has been attributed to the selective pressures 
associated with extensive use of broad-spectrum 
antimicrobials (cephalosporins, fluoroquinolones) and 
vancomycin [l-31. Recent reports of vancomycin- 
resistant enterococci isolated from the feces of poultry 
or swine and from the carcasses of food animals has 
intensified the debate concerning the likelihood of 
these species being a reservoir for pathogens causing 
both nosocomial and community-acquired infection in 
humans [4-81. The use of glycopeptides and other 
drugs in western Europe as growth promoters in food 
animals had been common practice [7,9]. Earlier 
studies had demonstrated cross-resistance between 
veterinary-use glycopeptides (avoparcin) and vanco- 
mycin or teicoplanin among enterococci of animal and 
human origin [5,10]. 
Alexomycin (U-82,127) is an antimicrobial com- 
plex that belongs to the cyclic peptide class [ l l ] .  It is a 
thiopeptide related to the sulfoinycins and is produced 
by Streptornyces arginensis. The reported spectrum of 
alexomycin includes Gram-positive pathogens, and 
the compound has been utilized to promote growth 
in weanling swine [12] with acceptable results at 
doses ranging from 3.3 to 55 mg/kg. The most recent 
investigation determined the most efficacious alexo- 
mycin dose range to be between 2.3 and 6.2 mg/kg 
[lo]. This peptide appears to be a promising candidate 
to complement or replace other compounds used in 
animal growth promotion [",lo], especially those 
glycopeptides that may select resistant strains thus 
complicating both animal and human antimicrobial 
chemotherapy [4-6,8,11,12]. In this report we 
summarize the in vitro characterization of alexomycin 
compared to two glycopeptides, a lipopeptide, selected 
p-lactams, macrolides, clindamycin, streptogramins, 
chloramphenicol, fluoroquinolones, and a tetracycline 
tested against three bacterial groups. 
The antimicrobial agents were obtained from the 
following manufacturers: alexomycin, cefiiofur and 
clindamycin from Pharmacia & Upjohn Pharma- 
ceuticals (Kalamazoo, MI, USA), avoparcin from 
Hof??nann-LaRoche (Basel, Switzerland), teicoplanin 
from Hoechst Marion-Roussel (Kansas City, MO, 
USA), vancomycin from Eli Lilly and Co. 
(Indianapolis, IN, USA), quinupristin/dalfopristin 
from Rhone-Poulenc Rorer (Collegeville, PA, USA), 
ciprofloxacin from Bayer (West Haven, CT, USA), and 
the remaining antimicrobial agents (ampicillin, 
erythromycin A, chloramphenicol, doxycycline) from 
Sigma Chemical Co. (St Louis, MO, USA). 
Minimum inhibitory concentrations (MICs) were 
determined by the broth microdilution method [14], 
and the interpretive criteria for susceptibility were 
those published by the National Committee for 
Clinical Laboratory Standards (NCCLS) [13]. Mueller- 
Hinton broth microdilution trays were manufactured 
by Prepared Media Laboratories (Wilsonville, O R ,  
USA) and stored at -7OOC until used. Quality control 
strains recommended by the NCCLS (Staphylococcus 
aureus ATCC 29213, Enterococcus faecalis ATCC 29212, 
Pseudomonas aeruginosa ATCC 27853, Escherichia coli 
ATCC 25922) were processed concurrently during in 
vitro susceptibility testing. The alexomycin activity 
against these strains revealed susceptibility among 
staphylococci (MICs, 0.12-0.5 mg/L), but resistance in 
Gram-negative bacilli (MIC, >32 mg/L). 
Table 1 illustrates the potent activity of alexomycin 
(MIC range, 0.06-0.5 mg/L) against a selected 
collection of 42 enterococcal strains. The majority 
of strains (24) had vanA-, vanB-, vanC1- or vanC2-3- 
mediated glycopeptide resistances, but remained 
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Table 1 Alexoniycin (U-82,227) in vitro activity compared to 11 other antimicrobial agents, tested against enterococci with 
various glycopeptide resistance patterns 
MICs (mg/L) for: 
Vancomycin susceptible (18 strains),' Vanconiycin resistant (23 strains)" 
Aritiiiiicrobial agents 51 1%) 90% k m g e  50%) 00% Kange 
Alesoniycin 
Avoparcin 
Teicoplanin 
Vancomycin 
Ainpicillin 
Ceftiofur 
Ervthromvcin 
Chndaniycin 
Quinupristin/dalfopristin 
Chloramphenicol 
Ciprofloxaciii 
Doxycyclinc 
0.12 
1 
11.12 
1 
<2 
> I 6  
4 
32 
8 
1 
4 
7 - 
0.25 
1 
0 5 
2 
>16 
> I 6  
>32 
>32 
4 
16 
2 8  
16 
n. 1 2-0.5 
0.5-2 
SO.(J1.5-1 
0.5-2 
52 to > I 6  
0.12->32 
1 to >32 
0.5-8 
4-16 
0.25 to >8 
0 06-16 
> I 6  
0.06-0. .5 
1 to >32 
0.06 to >32 
4 to >16 
52 to > I 6  
8 to > I 6  
0.12 to >32 
0.12 to >32 
0.25-16 
2-61 
0.25 to >8 
0.06-8 
~~~ ~ ~ ~ 
'Vaiicomycin-susceptible strains had negative PCX tests for vanA,  uanB, vnnCl or vuanCz-3 and MICs of <4 mg/L [13]. These isolates included: 
Eiitcrucocrusfaeculis (seven strains), Erirerococctrsfecium (eight strains), Enterucorrus dirrnns (two strains), and Enterururrirc auilrm (one strain). Eight 
of these strains (four Enterueoreirsfaecalis, three Eriterorocrusfaeciurii, one Enterococrtrs duranc) were isolated from animal\. 
Vanconiycin resistance was determned by the presence of a vanA,  uanB, u a n C ~  or uanC2-3 gene as determined by the I'CR t a t .  These 
strains included: Etiteroioccusfaecalis vatiA (two strains) and vanB (thrce strains), E,iterococcLts.fjecirrnr u a d  (five strains) and vutiB (fivc strains), 
Eriterococrus ,qalliriarirrri uanCl (seven strains), and Enteroiocrns cassel$auus iianC2-3 (two strains). None of these strains was from animal sources. 
Table 2 The antimicrobial activity of alexomycin (U-82,127) and 12 comparison compounds tested against 40 strains of 
Esrherichia coli" and 40 strains of Salmonella ~ p p . ~  
MIC (nig/L) 
Organism (no. tested) Antimicrobial agent 50% 90% Range 96 Susceptible' 
Ockerichia coli (40) Alexomycin 
Avoparcin 
Teicoplanin 
Vancomycin 
Anipicillin 
Penicillin 
Ceftiofur 
Erythromycin 
Clindamyciri 
Quinupristin/dalfopristin 
Chloramphenicol 
Ciprofloxacin 
Iloxycycline 
Sal~rrunella spp. (40) Alexoiiiycin 
Avoparcin 
Teicoplanin 
Vanconiycin 
Ampicillin 
Penicillin 
Ceftiofur 
Erythroniycin 
Clindaniycin 
Quinupristin/dalfopristin 
Chloramphenicol 
Ciprofloxacin 
Doxycycline 
>32 
>32 
>32 
> I 6  
4 
>1 
0.2.5 
>32 
>32 
>32 
8 
0.008 
2 
>32 
>32 
>32 
>16 
52 
> I  
1 
>32 
>32 
>32 
4 
0.015 
2 
>32 
>32 
>32 
>16 
> l h  
>1  
1 
>32 
>32 
>32 
8 
0.008 
32 
>32 
>32 
>32 
>16 
>16 
> I  
1 
>32 
>32 
>32 
8 
0.01 .5 
232 
>32 
>32 
> I 6  
52  to > I 6  
> I  
0.06-2 
16 to >32 
32 to ?I2 
>32 
>32 
2 to >fA 
SO.004-0.0.3 
0.5 to >32 
>32 
>32 
>32 
> 1 6 
S2 to >16 
> 1  
0.25-2 
32 to >32 
32 to >32 
2 to >64 
0.008-0.06 
0.5 tO >3? 
>32 
Includes 20 strains from animals and 20 strains from human infections. 
Includes 20 Salmoriella enteritidis strains isolated from humans and 20 strains of other Salrnuiiella spp. isolated from aninials (Snlwtorrella 
Susceptibility as defined by the NCCLS [14]. 
rholerae-suis, five strains; Sali?ionella typhimurium, right strains; Salmunello dublirr, four strains: Salmonella niburidaku, three straim) 
" No interpretive criteria have been established, but high MIC results indicate poor potential utility against these Gram-negative species. 
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susceptible to 10.5 mg/L of alexomycin. The most 
active comparison drugs tested were quinupristin/ 
dalfopristin (MIC5o, 1 or 2 mg/L), chloramphenicol 
(MIGO, 8 mg/L), and doxycycline (MIC~U, 0.12- 
4 mg/L). Quinupristin/dalfopr.istin was only effective 
against Enterococcusfaecium strains (all MICs, 1 2  mg/L). 
Avoparcin was less active than teicoplanin, but was 
generally more potent than vancomycin, against these 
enterococci. 
Enteritis-associated pathogens, Escherichia coli and 
Salmonella spp., were also tested, :many strains originating 
from cultures of humans and various animal species. As 
expected, the following compounds demonstrated little 
inhibitory action: alexomycin, avoparcin, teicoplanin, 
vancomycin, penicillin G, erythromycin A, clinda- 
niycin, and the streptogramin combination. Variable 
activity was noted for other drugs (53-100% suscept- 
ible) with ceftiofur, chloramphenicol and ciprofloxacin 
inhibiting > 90% of the 80 tested Enterobacteriaceae 
strains (Table 2). 
The search for antimicrobial agents that have 
activity against Gram-positive pathogens has led to 
structural modifications of existing classes as well as the 
study of sometimes older cornpounds with unique 
characteristics, e.g. everninomycin (SCH 27899), 
glycylcyclines, novobiocin, oxazolidinones, and alexo- 
mycin. The potency of alexomycin against vancomycin- 
resistant enterococci was excellent, and cross-resistance 
with other antimicrobials was not demonstrated among 
clinical isolates of enterococci. .Also, its spectrum does 
not include common enteric pathogens from the 
Enterobacteriaceae. Where glycopeptide-resistant enter- 
ococci may have already emerged in the flora of animal 
species, alexomycin appears to remain a viable 
alternative as a growth promoter [I 1,121, and no similar 
agent has been applied to therapy of human infections. 
This latter fact should limit the potential for inter- 
species transfer of resistance or the strains having 
developed genetic factors compromising chemotherapy 
of important clinical infections. 
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